

CURRICULUM VITAE

Name: Robert Lawrence Fenning, M.D.

Office: Medical University of South Carolina 843-792-4271
Hematology/Oncology Division 843-792-0644 (Fax)
Mail Stop Code 6350
96 Jonathan Lucas Street – 903 CSB
Charleston, SC 29425

EDUCATION:

Graduated from Peters Township High School
1952

Served in the United States Air Force
1953 - 1955

Pennsylvania State University
College Park, Pennsylvania; 1956 - 1960

University of Vermont College of Medicine (M.D.)
Nine Months Research with Dr. John Bland
Burlington, Vermont; 1960 - 1964

SPECIALTY CERTIFICATION:

May 2001	Recertification in Medical Oncology
October 1968	American Board of Internal Medicine - Part I
October 1970	American Board of Internal Medicine
January 1975	Diplomat in Subspecialty of Hematology
January 1976	Diplomat in Subspecialty of Medical Oncology

ADMINISTRATIVE APPOINTMENTS:

Present	Professor of Medicine, Hematology/Oncology Medical University of South Carolina Charleston, South Carolina
1969 - 1999	Practice of Internal Medicine, Hematology/Oncology On Active Staff at Charlotte Memorial Hospital Active Intern-Resident Teaching Program and Attending at Tumor Clinic and Hematology Clinic

Assistant Professor of Medicine
University of North Carolina
Charlotte, North Carolina

1967 - 1969 N. I. H. Fellowship
Primary Training in Clinical Hematology/Oncology
Mayo Clinic
Rochester, Minnesota

1965 - 1967 Medical Residence
Mayo Clinic
Rochester, Minnesota

1964 - 1965 Mixed Internship
Robert Packers Hospital
Sayre, Pennsylvania

PROFESSIONAL ORGANIZATION MEMBERSHIPS:

1969 Mecklenburg County Medical Society
1969 North Carolina Medical Society
1969 American Medical Society
1970 American Society of Internal Medicine
1971 American College of Physicians
1985 ASCO
1992 Southern Medical Society

BOARD MEMBERSHIPS:

1978 - 1979 Board of Directors, American Cancer Society
Mecklenburg Unit

1978 - 1979 Chairman, Department of Medicine
Charlotte Memorial Hospital

Board of Directors
Hospice of North Carolina

CLINICAL RESEARCH ACTIVITIES:

Comparison of CGS-16949A Versus Megestrol Acetate in Post-Menopausal Women with Breast Carcinoma Protocol - 03; Co-Investigator; Completed 10/93; Ciba Geigy.

Poly: Poly C₁₂^u (Ampligen) Code - BB-Ind 2252. In The Treatment of NSCLC.

Phase IV Clinical Evaluation of Procrit in Anemic Cancer Patients receiving Chemotherapy; Completed 03/94; Kern McNeil-Ortho BioTech.

A Randomized Double-Blind, Placebo-Controlled Multicenter Study of Oral GR122311X Compared with Ranitidine and GR8850502X for the Prophylaxis of Nonsteroidal Anti-Inflammatory Drug Associated Gastric or Duodenal Ulcers in Patient with Osteo-Rheumatoid Arthritis and Without a History of Gastric or Duodenal Ulcers; Protocol H2B-341; Principal Investigator; Completed 04/94; Glaxo.

Letrozole (CGS 20267) Comparison of Two Doses (0.5 mg. and 2.5 mg.) of Letrozole Versus Megestrol Acetate in Post-Menopausal Women with Breast Cancer; Protocol 02; Principal Investigator; Ciba Geigy

PUBLICATIONS:

1. Vinay Gudena, Nitin Verma, Ginell Post, Michael Kizziah, **Robert Fenning**, and Alberto J. Montero. Bedside-to-Bench Report: Metastatic Chest Wall Malignant Schwannoma Responding to Sorafenib. *Cancer Biology & Therapy* 7:4, 1-4; April 2008.
2. John Hayslip, **Robert Fenning**. Safe Administration of Iodine-131 Tositumomab After Repeated Infusion-Related Reactions to Rituximab. *The Oncologist Lymphoma* 2007; 12:000-000